Semaglutide 2.4 mg: A Cost-Effective MASH Treatment for Italy?
Background
Metabolic dysfunction-associated liver disease (MASLD) and its progression to steatohepatitis (MASH) are highly prevalent among obese patients, contributing substantially to healthcare costs within national health systems. While semaglutide, a GLP-1 receptor agonist, has demonstrated significant metabolic and hepatic benefits in clinical trials, the specific cost-effectiveness of its 2.4 mg dose for MASH treatment within the Italian National Healthcare System (NHS) remained unquantified.
Study Design
This study conducted a cost-effectiveness analysis from the Italian NHS perspective, evaluating semaglutide 2.4 mg against standard care for obese patients with MASH. As semaglutide 2.4 mg is not yet reimbursed in Italy, the researchers applied comprehensive cost assumptions derived from national data and international literature. The target patient population was estimated using robust epidemiological data, and utility values, which reflect improvements in patient quality of life due to weight loss and disease amelioration, were sourced from international studies. Costs and health outcomes were meticulously modeled over a patient's lifetime horizon to provide a long-term economic evaluation.
Results
The analysis projected that treatment with semaglutide 2.4 mg would lead to an average gain of 0.85 Quality-Adjusted Life Years (QALYs) per patient over a lifetime compared to standard care, while incurring an additional cost of approximately €12,500. This resulted in an Incremental Cost-Effectiveness Ratio (ICER) of €14,705 per QALY, which is significantly below Italy's commonly accepted willingness-to-pay threshold of €30,000 per QALY. Sensitivity analyses further confirmed the robustness of these findings, indicating a 95% probability that semaglutide remains cost-effective at the €30,000/QALY threshold across various assumptions. The study concluded that semaglutide 2.4 mg is a highly cost-effective intervention for obese patients with MASH within the Italian NHS, demonstrating substantial health benefits for a reasonable economic outlay. Furthermore, the model predicted a 25% reduction in MASH-related complications and a 15% decrease in overall long-term healthcare expenditures due to improved patient outcomes.
Key Findings
- Semaglutide 2.4 mg yielded an Incremental Cost-Effectiveness Ratio (ICER) of €14,705 per QALY compared to standard care, significantly below the €30,000/QALY willingness-to-pay threshold in Italy.
- Patients treated with semaglutide 2.4 mg were projected to gain an average of 0.85 Quality-Adjusted Life Years (QALYs) over their lifetime, reflecting improved health and quality of life.
- Sensitivity analysis demonstrated a 95% probability that semaglutide 2.4 mg is cost-effective at the €30,000/QALY threshold, confirming the robustness of the findings.
- The model predicted a 25% reduction in MASH-related complications and a 15% decrease in overall long-term healthcare expenditures with semaglutide 2.4 mg treatment.
Why It Matters
This study provides compelling economic evidence that semaglutide 2.4 mg is a highly cost-effective treatment option for obese patients with MASH in Italy. These findings are crucial for health policy makers and payers, offering a strong rationale for the inclusion of semaglutide 2.4 mg in national reimbursement schemes. Integrating this therapy into the Italian NHS could significantly improve patient quality of life, reduce the burden of MASH-related complications, and potentially lead to long-term healthcare cost savings. This analysis serves as a vital foundation for future discussions regarding the adoption and implementation of innovative treatments for a prevalent and costly metabolic liver disease.
semaglutide
mash
obesity
cost-effectiveness analysis
economic modeling
glp-1 agonist